{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:09:25Z","timestamp":1787317765979,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"\n Background:<\/jats:title>\n An inactivated Vero cell culture derived Japanese encephalitis virus vaccine (IXIARO) requires a booster dose 1 year after primary schedule for long-term antibody persistence in adults. The aim of this study is to evaluate immunogenicity and safety of a booster dose in children 2 months to <18 years of age.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This is a randomized, controlled open-label study in the Philippines. Three hundred children vaccinated with IXIARO in a previous trial were randomized 1:1 to receive either no booster or a booster 12 months after initiation of the primary series. Neutralizing antibody titers were assessed before and after the booster and up to 3 years after primary series. Safety endpoints included the rate of subjects with solicited adverse events (AEs), unsolicited AEs and serious AEs within 1 month after the booster.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Geometric mean titer declined by 1 year after the primary series, but titers remained above the established protective threshold in 85%\u2013100% of children depending on age group. The booster led to a pronounced increase in geometric mean titer and 100% seroprotection rate in all age groups. The booster was well tolerated, with AE rates lower compared with the primary series. Most AEs were mild.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n A booster dose of IXIARO administered 12 months after the primary immunization was well tolerated and highly immunogenic.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/inf.0000000000002124","type":"journal-article","created":{"date-parts":[[2018,6,17]],"date-time":"2018-06-17T06:45:51Z","timestamp":1529217951000},"page":"e233-e240","source":"Crossref","is-referenced-by-count":15,"title":["Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose"],"prefix":"10.1097","volume":"37","author":[{"given":"Vera","family":"Kadlecek","sequence":"first","affiliation":[{"name":"Valneva Austria GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa Fay","family":"Borja-Tabora","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Eder-Lingelbach","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvacion","family":"Gatchalian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"},{"name":"College of Medicine, University of the Philippines, Manila, Philippines"},{"name":"Section of Infectious and Tropical Diseases, Department of Pediatrics, Philippine General Hospital, Manila, Philippines"},{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Kiermayr","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Sablan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kundi","sequence":"additional","affiliation":[{"name":"Center for Public Health, Medical University of Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Taucher","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin L.","family":"Dubischar","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.68.4.405","article-title":"Japanese encephalitis.","volume":"68","author":"Solomon","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review.","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(97)07509-0","article-title":"Poliomyelitis-like illness due to Japanese encephalitis virus.","volume":"351","author":"Solomon","year":"1998","journal-title":"Lancet"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4269\/ajtmh.1958.7.365","article-title":"Factors influencing transmission of Japanese B encephalitis virus by a colonized strain of Culex tritaeniorhynchus Giles, from infected pigs and chicks to susceptible pigs and birds.","volume":"7","author":"Gresser","year":"1958","journal-title":"Am J Trop Med Hyg"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4049\/jimmunol.83.6.605","article-title":"Immunologic studies of Japanese encephalitis virus in Japan. III. Infection and antibody responses of birds.","volume":"83","author":"Buescher","year":"1959","journal-title":"J Immunol"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4269\/ajtmh.13-0161","article-title":"Age-related susceptibility to Japanese encephalitis virus in domestic ducklings and chicks.","volume":"90","author":"Cleton","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"R7-20230912","first-page":"331","article-title":"Japanese encephalitis vaccines.","volume":"81","year":"2006","journal-title":"WHO, World Health Organization Releve epidemiologique hebdomadaire"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/BC.2008.062","article-title":"Japanese encephalitis vaccines\u2013needs, flaws and achievements.","volume":"389","author":"Tauber","year":"2008","journal-title":"Biol Chem"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1586\/erv.12.100","article-title":"Vaccinating against Japanese encephalitis virus: what have we learned from recent clinical trials?","volume":"11","author":"Dubischar-Kastner","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.vaccine.2011.01.058","article-title":"Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO\u00ae, IC51.","volume":"29","author":"Eder","year":"2011","journal-title":"Vaccine"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/INF.0000000000001615","article-title":"Immunogenicity of the inactivated Japanese encephalitis virus vaccine IXIARO in children from a Japanese encephalitis virus-endemic region.","volume":"36","author":"Dubischar","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/INF.0000000000001623","article-title":"Safety of the inactivated Japanese encephalitis virus vaccine IXIARO in children: an open-label, randomized, active-controlled, phase 3 study.","volume":"36","author":"Dubischar","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004.","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1016\/j.vaccine.2015.05.037","article-title":"Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.","volume":"33","author":"Paulke-Korinek","year":"2015","journal-title":"Vaccine"},{"key":"R21-20230912","first-page":"811","article-title":"Statistical models for predicting the duration of vaccine-induced protection.","volume":"33","author":"Pigeon","year":"1999","journal-title":"Therapeutic Innovation & Regulatory Science Sage Journals"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201809000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:30:08Z","timestamp":1694543408000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201809000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002124","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}